Cancer research communications · 2025
Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia.
СтатьяПоддержка правительства СШАПоддержка NIH: внешняя программаНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guillen Magaña Jamie N, Zannikou Markella, Baran Aneta, Small Sara, Schieber Michael, Schipma Matthew J, Bartom Elizabeth T, Kocherginsky Masha, Saleiro Diana, Beauchamp Elspeth M, Eckerdt Frank, Platanias Leonidas C
Аннотация
UNLABELLED: We examined the role of SLFN12, a member of the Schlafen (SLFN) family of interferon-regulated genes and proteins in leukemogenesis, and its potential as a therapeutic target in acute myeloid leukemia (AML). We explored the effects of velcrins, a class of small molecules able to modulate SLFN12 biological activity, on AML cells. Velcrin treatment of AML cells stabilized SLFN12 and promoted SLFN12 complex formation with phosphodiesterase 3A or phosphodiesterase 3B. Such effects were associated with growth-inhibitory and proapoptotic responses, as well as potent suppressive effects on leukemic cell growth. In addition, velcrin treatment suppressed clonogenic capacity of primitive leukemic progenitors and significantly extended survival in a mouse AML xenograft model. Taken together, these findings establish an important role of SLFN12 in leukemogenesis and raise the potential for the use of velcrins as a therapeutic strategy for AML.
SIGNIFICANCE: Our studies identify SLFN12 as a potential target in AML with important clinical-translational implications.
SIGNIFICANCE: Our studies identify SLFN12 as a potential target in AML with important clinical-translational implications.